Vaxxas

About:

Vaxxass is a biotechnology company focused on needle-free vaccination technology.

Top Investors: Wellcome Trust, Bill & Melinda Gates Foundation, Biomedical Advanced Research and Development Authority (BARDA), OneVentures, Brandon Capital

Description:

Vaxxass is a biotechnology company that develops a novel needle-free vaccination technology. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine "cold chain". Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.

Total Funding Amount:

$103M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Brisbane, Queensland, Australia

Founded Date:

2011-01-01

Founders:

Mark Kendall

Number of Employees:

51-100

Last Funding Date:

2023-08-23

IPO Status:

Private

Industries: